Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR750 Phase 1 bridging study in Chinese healthy subjects
NCT06932536Phase 1Completed
- Sponsor
- Shanghai SIMRD Biotechnology Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SR750 tablet with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration at 48 hours, Time to Maximum Plasma Concentration at 48 hours and 4 more. Started Apr 2025; status: completed.
02
Drugs
SR750
Beyond the preview
Go deeper on NCT06932536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932536.